**ABSTRACT AUTHORS**

**Contact Information**

|  |  |  |  |
| --- | --- | --- | --- |
| **LAST NAME** | **FIRST NAME** | **TITLE** | **EMAIL** |
| ADILI | ALI | IL-10 IN TRIPLE NEGATIVE METASTATIC BREAST CANCER | [ALI.ADILI@MOFFITT.ORG](mailto:ALI.ADILI@MOFFITT.ORG) |
| AGGARWAL | VAISHALI | INTERFERON-Γ, A MASTER REGULATOR DRIVING IMMUNE RESPONSE AND T-CELL EXHAUSTION | [VAA30@PITT.EDU](mailto:VAA30@PITT.EDU) |
| AHMED | AML | STUDY OF PI3K ONCOGENE ADDICTION IN NON-SMALL CELL LUNG CANCER (NSCLC) | [AAHMED6@MDANDERSON.ORG](mailto:AAHMED6@MDANDERSON.ORG) |
| BHATIA | ISHAN | HELPING TO DEVELOP NOVEL CAR-T CELL THERAPY FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN INDIA | [IIBHATIA97@GMAIL.COM](mailto:IIBHATIA97@GMAIL.COM) |
| CHAKRABORTY | SRIJA | ENHANCING NATURAL KILLER CELL HOMING TO MELANOMA ORGANOIDS IN A TUMOR-ON-A-CHIP PLATFORM VIA INDUCTION OF TUMOR-CELL SECRETED CHEMOKINES | [CHAKRABORTY.117@BUCKEYEMAIL.OSU.EDU](mailto:CHAKRABORTY.117@BUCKEYEMAIL.OSU.EDU) |
| CHEN | YU-HIS | TITERING CAR EXPRESSION ON PRIMARY T CELLS ENABLED BY MICROFLUIDIC BASED DOSAGE CONTROLLED INTRACELLULAR DELIVERY PLATFORM | [YUHSIC6@UCI.EDU](mailto:YUHSIC6@UCI.EDU) |
| CHOUKRANI | GHIZLANE | GALECTIN-9 SHIFTS THE PHAGOCYTIC BALANCE ON CANCER CELLS AND TRIGGERS NEUTROPHIL-MEDIATED ANTICANCER IMMUNITY. | [GHIZLANCHOUKRANI@GMAIL.COM](mailto:GHIZLANCHOUKRANI@GMAIL.COM) |
| CHUKWUKERE | CHINAZAEKPERE | IMMUNOTHERAPY - PINEAPPLE, AND COLOSTRUM FROM BREASTMILK CAN BE THE MISSING PUZZLE IN DEFINITE CANCER TREATMENT. | [NAZYCHUKS01@GMAIL.COM](mailto:NAZYCHUKS01@GMAIL.COM) |
| DAR | MUKHTAR AHMAD | DESIGNING OF PEPTIDE BASED MULTI-EPITOPE VACCINE CONSTRUCT AGAINST GALLBLADDER CANCER USING  IMMUNOINFORMATICS AND COMPUTATIONAL APPROACHES | [DARMUKTHAR55@GMAIL.COM](mailto:DARMUKTHAR55@GMAIL.COM) |
| GUNTURI | ALEKHYA | CHARACTERIZATION OF NOVEL ANTI-TIGIT ANTIBODIES FOR POTENTIAL ANTI-TUMOR ACTIVITY | [AGUNTURI@BU.EDU](mailto:AGUNTURI@BU.EDU) |
| HAGAR | AMIT | AN INTEGRATED VIRTUAL TISSUE PLATFORM FOR INCORPORATING EXERCISE ONCOLOGY INTO IMMUNOTHERAPY | [AMITHAGAR@GMAIL.COM](mailto:AMITHAGAR@GMAIL.COM) |
| HUANG | YUE | MESOPOROUS SILICA NANOPARTICLES AS ROS SENSITIVE CARRIER FOR THERAVAC REGIMEN ENHANCE THE LOCAL IMMUNE RESPONSE IN MICE | [YUE.HUANG@NIH.GOV](mailto:YUE.HUANG@NIH.GOV) |
| JALBUENA | AMANGELIN | DEFINING T-CELL RESPONSES TO MUTANT AND NON-MUTANT ANTIGENS IN MOUSE MELANOMA DURING ANTI-CTLA-4 IMMUNE CHECKPOINT THERAPY | [ADJALBUENA@GMAIL.COM](mailto:ADJALBUENA@GMAIL.COM) |
| KARALIOTA | SEVASTI | HETERODIMERIC IL-15 (HETIL-15) IMMUNOTHERAPY REVERSES CD8+T CELL METABOLIC DYSFUNCTION IN MURINE BREAST TUMORS | [SEVASTI.KARALIOTA@NIH.GOV](mailto:SEVASTI.KARALIOTA@NIH.GOV) |
| KNIGHT | JULIA | ALDH INHIBITION AS MODULATOR OF OVARIAN TUMOR ASSOCIATED MACROPHAGES | [JCK81@PITT.EDU](mailto:JCK81@PITT.EDU) |
| KONDURI | VANAJA | DENDRITIC CELL GOVERNANCE OF AN INNATE-LIKE CYTOTOXIC EFFECTOR MEMORY  CD8+CD161+ T CELL SUBSET | [KONDURI@BCM.EDU](mailto:KONDURI@BCM.EDU) |
| LEYFMAN | YAN | IMPROVING HEALTHCARE ACCESS THROUGH THE DEVELOPMENT OF AN ONTOLOGY PLATFORM TO CONNECT BALT PATIENTS INFECTED WITH COVID-19 TO IMMUNOTHERAPEUTIC CLINICAL TRIALS | [YANLEYFMAN7@GMAIL.COM](mailto:YANLEYFMAN7@GMAIL.COM) |
| LIU | WENLONG | ANTI-MESOTHELIN IMMUNOTOXIN LMB-100 INDUCES COMPLETE TUMOR REGRESSIONS OF PERITONEAL MESOTHELIOMA, ANTI-TUMOR IMMUNITY AND THE DEVELOPMENT OF TERTIARY LYMPHOID STRUCTURE (TLS) | [LIUW11@NIH.GOV](mailto:LIUW11@NIH.GOV) |
| MAJUMDAR | SHUBHABRATA | FINE-TUNING CHIMERIC ANTIGEN RECEPTOR SIGNALING BY REDUCING CD3Ζ ITAM DIVERSITY | [SHUBHABRATA92@GMAIL.COM](mailto:SHUBHABRATA92@GMAIL.COM) |
| MARLIN ANDREWS | CELINE | HARNESSING THE INNATE IMMUNE RESPONSE FOR POTENTIAL MALIGNANT MELANOMA THERAPY | [CMANDREWS@VT.EDU](mailto:CMANDREWS@VT.EDU) |
| MARTIN | SUNIL | EXPANSION AND TRANSDUCTION OF HUMAN Γ9Δ2 T CELLS TO TARGET  HEMATOLOGIC MALIGNANCIES | [SUNILMARTIN03@GMAIL.COM](mailto:SUNILMARTIN03@GMAIL.COM) |
| MASTROPAOLO | MARIA | PATIENT-DERIVED ORGANOIDS MODEL SENSITIVITY AND RESISTANCE TO PARP INHIBITORS IN PATIENTS WITH METASTATIC COLORECTAL CANCER | [MARIAMASTRO143@GMAIL.COM](mailto:MARIAMASTRO143@GMAIL.COM) |
| MHIBIK | MAISSA | TREATMENT WITH BTK INHIBITOR OR BCL-2 INHIBITOR ENHANCES CYTOTOXICITY OF THE ANTI-CD3XCD20 BISPECIFIC ANTIBODY EPCORITAMAB AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA | [MAISSA.MHIBIK@NIH.GOV](mailto:MAISSA.MHIBIK@NIH.GOV) |
| MOHANTY | AYUSHI | COMBINED DRUG EFFICACY IN PRECLINICAL MODELS OF COLORECTAL CANCER | [2AYUSHIM@GMAIL.COM](mailto:2AYUSHIM@GMAIL.COM) |
| MOORE | EMILY | CHARTING THE TUMOR-REACTIVE T CELL REPERTOIRE IN DNA DAMAGE REPAIR (DDR) DEFICIENT PANCREATIC CANCER TOWARDS PERSONALIZED T-CELL THERAPY | [EKM2150@CUMC.COLUMBIA.EDU](mailto:EKM2150@CUMC.COLUMBIA.EDU) |
| MUELLER | JUERGEN | DELETION OF NK CELLS AND RE-DIRECTING OF DENDRITIC CELL DIFFERENTIATION DURING T LYMPHOMA DEVELOPMENT IN MICE | [MUELLERJ@MAIL.NIH.GOV](mailto:MUELLERJ@MAIL.NIH.GOV) |
| NAHAR | SAIFUN | EFFECTIVE IMMUNOTHERAPEUTIC REGIMEN WITH COMBINATIONS OF TLR AGONISTS AND IMMUNE CHECK POINT  BLOCKADE AGAINST MOUSE 4T1 BREAST CARCINOMA | [NAHARS2@NIH.GOV](mailto:NAHARS2@NIH.GOV) |
| NCEMBU | SIKOZILE | RECOMBINANT CD-64 DIRECTED SINGLE-CHAIN ANTIBODY FUSION PROTEIN EXHIBITS CYTOTOXICITY AND IS  A TOOL FOR SITE-SPECIFIC DIAGNOSIS OF ACUTE MYELOID LEUKEMIA | [SIKOZILENCEMBU@GMAIL.COM](mailto:SIKOZILENCEMBU@GMAIL.COM) |
| NISAR | ALBEENA | IMPLEMENTING FAST TRACK COST EFFECTIVE PROCESS DEVELOPMENTAL STRATEGIES AND QUALITY BY DESIGN APPROACH FOR SUCCESSFUL TRANSITION OF CELL BASED IMMUNOTHERAPEUTIC PRODUCTS INTO CLINICS - THE EXPERIENCE FROM THE FIRST CAR T & CELL THERAPY CENTRE IN INDIA | [NISARALBEENA15@GMAIL.COM](mailto:NISARALBEENA15@GMAIL.COM) |
| ONDA | MASANORI | 15B6 CAR T CELLS THAT BIND TO A JUXTAMEMBRANE REGION OF MESOTHELIN AND ARE NOT BLOCKED BY SHED MESOTHELIN | [ONDAM@MAIL.NIH.GOV](mailto:ONDAM@MAIL.NIH.GOV) |
| OUCHEN | KHAOULA | OPTIMIZED LENTIVIRAL VECTOR DESIGN FOR ON-COMMAND GENE-CARGO DELIVERY BY ENGINEERED T CELLS | [OUCHENKHAOULA1@GMAIL.COM](mailto:OUCHENKHAOULA1@GMAIL.COM) |
| PATKAR | SUSHANT | TUMOR MICROENVIRONMENT (TME) LANDSCAPE DICTATES METASTATIC PROGRESSION AND TREATMENT SENSITIVITY OF CANINE AND HUMAN OSTEOSARCOMAS | [PATKAR.SUSHANT@NIH.GOV](mailto:PATKAR.SUSHANT@NIH.GOV) |
| PRITAM | MANISHA | DEVELOPMENT OF LAG3 IMMUNE CHECKPOINT INHIBITORS FOR CANCER TREATMENT BY USING BIOINFORMATICS APPROACHES | [MANISHA.PRITAM@NIH.GOV](mailto:MANISHA.PRITAM@NIH.GOV) |
| SANYAL | SREYA | IMMUNOLOGICAL FEATURES AFFECTING GASTRIC TUMOR SENSITIVITY TO PD-1/PD-L1 INHIBITORS | [SREYASCIENCE@GMAIL.COM](mailto:SREYASCIENCE@GMAIL.COM) |
| SMITH-UFFEN | MEGAN | ESTIMATING SCENARIOS FOR SURVIVAL TIME IN PATIENTS WITH METASTATIC MELANOMA RECEIVING IMMUNOTHERAPY OR TARGETED THERAPY | [SMITHUFFEN.M@GMAIL.COM](mailto:SMITHUFFEN.M@GMAIL.COM) |
| SMITH-UFFEN | MEGAN | IMMUNE CHECKPOINT INHIBITOR-INDUCED POLYARTHRITIS: A CASE SERIES | [SMITHUFFEN.M@GMAIL.COM](mailto:SMITHUFFEN.M@GMAIL.COM) |
| STRAVOKEFALOU | VASILIKI | REDUCTION OF CIRCULATING TUMOR CELLS AND METASTASIS FORMATION BY HETERODIMERIC IL-15 (HETIL-15) IMPROVES CHEMOTHERAPY AND SURGERY OUTCOME | [VASILIKI.STRAVOKEFALOU@NIH.GOV](mailto:VASILIKI.STRAVOKEFALOU@NIH.GOV) |
| UGUZOVA | SABINE | PREDICTIVE VALUE OF CT SCANS AT 3 AND 6 MONTHS ON OVERALL SURVIVAL IN PATIENTS WITH METASTATIC RENAL CANCER ON 2ND AND LATER LINE NIVOLUMAB | [UGUZOVA.SABINE@GMAIL.COM](mailto:UGUZOVA.SABINE@GMAIL.COM) |
| VIGANT | FREDERIC | IN VIVO GENERATION OF TUMOR-METABOLISM-REGULATED HER-2-SPECIFIC CAR+ CELLS ERADICATE ESTABLISHED HER2+ GASTRIC CARCINOMAS WITH THE NOVEL SUBCUTANEOUS ROUTE OF ADMINISTRATION OF CD3-DIRECTED LENTIVECTOR-LOADED LYMPHOCYTES | [FVIGANT@EXUMABIO.COM](mailto:FVIGANT@EXUMABIO.COM) |
| VOYNOVA | ELISAVETA | INCREASED ACTIVITY OF A NK-SPECIFIC CAR-NK FRAMEWORK TARGETING CD3 AND CD5 FOR T-CELL LEUKEMIAS | [ELISAVETA.VOYNOVA@NIH.GOV](mailto:ELISAVETA.VOYNOVA@NIH.GOV) |
| WANG | BINBIN | DECOUPLING CYTOTOXIC T LYMPHOCYTE AND EXHAUSTED T LYMPHOCYTE TRANSCRIPTOMIC  SIGNATURES ENHANCES IMMUNE CHECKPOINT INHIBITORS RESPONSE PREDICTION IN MELANOMA | [BINBIN.WANG@NIH.GOV](mailto:BINBIN.WANG@NIH.GOV) |
| WARD | ROSS | INFLAMMASONE ACTIVATING NANOPARTICLES PROMOTE PROTECTIVE ANTI-TUMOUR CD8+ T CELLS | [WARDRO@TCD.IE](mailto:WARDRO@TCD.IE) |
| YOSHIMOTO | SHO | PD-1CD28 SWITCH RECEPTOR OVERCOMES PD-L1 MEDIATED INHIBITION OF CANINE CAR-T CELLS | [YSHO@VET.UPENN.EDU](mailto:YSHO@VET.UPENN.EDU) |
| ZENS | STEFAN | CHARTING THE TUMOR-REACTIVE T CELL REPERTOIRE IN DNA DAMAGE REPAIR (DDR) DEFICIENT PANCREATIC CANCER TOWARDS PERSONALIZED T-CELL THERAPY | [S.ZENS@DKFZ-HEIDELBERG.DE](mailto:S.ZENS@DKFZ-HEIDELBERG.DE) |